thought call
 trend could aid transform deal although normal
season neg impact ibranc xeljanz like overlook
viagra loe enbrel eu biosimilar competit hospira-rel product shortag
also neg impact top-lin perform miss stark remind
continu face numer headwind attempt achiev meaning
growth contribut recent downgrad see biopharmaceut
encourag sign across innov
portfolio y/i oper ibranc xeljanz eliqui capabl help
drive mid-singl digit growth late-stag pipelin either fail impress
oncolog unlik move needl significantli present scale rare
diseas note declin rais either revenu and/or ep guidanc
unlik mani peer earn season reason
continu believ transform deal remain biggest potenti valu driver
emphasi strateg rational return metric said
manag adopt cautiou tone signific busi develop
continu see share rang bound maintain ew pt
pipelin updat oncolog intend file talazoparib mbc pdufa
date assign lorlatinib alk nsclc aug dacomitinib egfr
nsclc sep vaccin enrol phase difficil continu well
on-going phase aureu trial may expand pivot addit phase
rivipansel sickle-cel tanezumab pain remain track read-out later year
model chang modestli increas sale
midpoint current compani guidanc also increas
outlook line pre-earn consensu year
opex increas line estim adjust dilut ep
respect
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
larg captur upsid key product
prevnar ibranc xtandi absent meaning
busi development/ acquisit see littl
upsid current revenu earn trend
better expect uptak prevnar ibranc
xtandi offset price pressur essenti
coupl pipelin success oncolog
success deploy capit toward could
result upsid forecast
faster eros essenti due price
pressur along lower growth innov could
result weaker top line growth failur deploy
capit pipelin asset could cloud
long-term outlook result share stay
million except per share itemspriorcurr chg amort incom attribut common item net ep ep outstand outstand analysiscurrentcurr chgchg bp gross changecurrentcurr chgchg incom incom million except per share itemspriorcurr chg amort incom attribut common item net ep ep outstand outstand analysiscurrentcurr chgchg bp gross changecurrentcurr chgchg incom incom barclay inc
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
